ADAMTS12

Across TCGA pan-cancer cohorts, ADAMTS12 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ADAMTS12 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher ADAMTS12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS12 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

PAAD, LUAD, and BRCA are the cancer types where ADAMTS12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.077	0.647	<.001	24	view →
LUAD	DFS	Median	II,III,IV	0.554	0.700	.006	24	view →
BRCA	OS	Median	II,III,IV	0.599	0.913	<.001	20	view →
UCEC	DFS	Median	All	0.929	0.610	.004	14	view →
BLCA	DFS	Median	III,IV	1.000	0.179	.015	13	view →
SARC	OS	Median	All	0.109	0.827	<.001	12	view →
GBM	OS	Median	All	0.772	0.393	.021	10	view →
SKCM	OS	Median	IV	0.247	0.721	.038	4	view →
THCA	OS	Median	All	0.342	0.955	.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	OS	Median	II,III,IV	0.906	0.705	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ADAMTS12–PAAD (OS)

Open the PAAD breakdown →